Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

Amanda Psyrri, Tanguy Y. Seiwert, Stefan Kasper et al.|Annals of Oncology|2022

Cited by 144